These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12520482)

  • 1. Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients.
    Strouse C; Mott SL; Smith BJ; Magalhaes-Silverman M; Farooq U; Zhan F; Jethava Y; Tricot G
    Bone Marrow Transplant; 2024 Jan; 59(1):128-130. PubMed ID: 37816907
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
    Prince HM; Adena M; Smith DK; Hertel J
    Eur J Haematol; 2007 Aug; 79(2):93-9. PubMed ID: 17608711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How best to use new therapies in multiple myeloma.
    Dingli D; Rajkumar SV
    Blood Rev; 2010 May; 24(3):91-100. PubMed ID: 20359801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging treatments for multiple myeloma.
    Schwartz RN; Vozniak M
    J Manag Care Pharm; 2008 Sep; 14(7 Suppl):12-9. PubMed ID: 18774881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Arkansas approach to therapy of patients with multiple myeloma.
    Barlogie B; Anaissie E; van Rhee F; Pineda-Roman M; Zangari M; Shaughnessy J; Epstein J; Crowley J
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):761-81. PubMed ID: 18070718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.
    Mitsiades CS; Davies FE; Laubach JP; Joshua D; San Miguel J; Anderson KC; Richardson PG
    J Clin Oncol; 2011 May; 29(14):1916-23. PubMed ID: 21482978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs.
    Huynh M; Chang HY; Lisiero DN; Ong IM; Kashyap T; Callander NS; Miyamoto S
    PLoS One; 2022; 17(12):e0274704. PubMed ID: 36480501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma.
    Pisano M; Cheng Y; Sun F; Dhakal B; D'Souza A; Chhabra S; Knight JM; Rao S; Zhan F; Hari P; Janz S
    Front Immunol; 2021; 12():667054. PubMed ID: 34149703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
    Lee AH; Iwakoshi NN; Anderson KC; Glimcher LH
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9946-51. PubMed ID: 12902539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy and immunomodulatory drugs in multiple myeloma.
    Barlogie B; Shaughnessy J; Zangari M; Tricot G
    Semin Oncol; 2002 Dec; 29(6 Suppl 17):26-33. PubMed ID: 12520482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
    Barlogie B
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):33-8. PubMed ID: 15015894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.